Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1636-1642

  Xie, Xue Mei ^a,b   Zhang, Zi Yin ^c   Yang, Lian He ^a   Yang, Da Lei ^a   Tang, Na ^a   Zhao, Huan Yu ^a   Xu, Hong Tao ^a   Li, Qing Chang ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

^c Meishan Sichuan 620010   (China)

Author keywords

Disabled 2; Invasion; Lung cancer; Methylation; Proliferation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA CATENIN; DISABLED 2 PROTEIN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; DEMETHYLATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; TUMOR INVASION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84885053720     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2084     Document Type: Article

References (30)

1. Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129: 199-221, 2003.
2. Prunier C, Hocevar BA and Howe PH: Wnt signaling: physiology and pathology. Growth Factors 22: 141-150, 2004.
3. Kimelman D and Xu W: beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25: 7482-7491, 2006.
4. MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
5. Jiang Y, Luo W and Howe PH: Dab2 stabilizes Axin and attenuates Wnt/beta-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions. Oncogene 28: 2999-3007, 2009.
6. He X, Semenov M, Tamai K and Zeng X: LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131: 1663-1677, 2004.
7. Zeng X, Tamai K, Doble B, et al: A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438: 873-877, 2005.
8. Gertler FB, Bennett RL, Clark MJ and Hoffmann FM: Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell 58: 103-113, 1989.
9. Kim JA, Bae SH, Choi YJ, Kim KH and Park SS: Feed-back regulation of disabled-2 (Dab2) p96 isoform for GATA-4 during differentiation of F9 cells. Biochem Biophys Res Commun 421: 591-598, 2012.
10. Fu L, Rab A, Tang LP, Rowe SM, Bebok Z and Collawn JF: Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator. Biochem J 441: 633-643, 2012.
11. Hung WS, Huang CL, Fan JT, Huang DY, Yeh CF, Cheng JC and Tseng CP: The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen. Biochim Biophys Acta 1823: 1778-1788, 2012.
12. Hocevar BA, Smine A, Xu XX and Howe PH: The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 20: 2789-2801, 2001.
13. Jiang Y, Prunier C and Howe PH: The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin. Oncogene 27: 1865-1875, 2008.
14. Jiang Y, He X and Howe PH: Disabled-2 (Dab2) inhibits Wnt/beta-catenin signalling by binding LRP6 and promoting its internalization through clathrin. EMBO J 31: 2336-2349, 2012.
15. Karam JA, Shariat SF, Huang HY, et al: Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13: 4400-4406, 2007.
16. Yang DH, Smith ER, Cohen C, et al: Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 94: 2380-2392, 2002.
17. Kleeff J, Huang Y, Mok SC, Zimmermann A, Friess H and Büchler MW: Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis Colon Rectum 45: 1242-1248, 2002.
18. Anupam K, Tusharkant C, Gupta SD and Ranju R: Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol 12: 6041-6045, 2006.
19. Chetrit D, Barzilay L, Horn G, Bielik T, Smorodinsky NI and Ehrlich M: Negative regulation of the endocytic adaptor disabled-2 (Dab2) in mitosis. J Biol Chem 286: 5392-5403, 2011.
20. Yang DH, Smith ER, Roland IH, et al: Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. Dev Biol 251: 27-44, 2002.
21. Zhu W, Zheng J and Fang W: Isolation and characterization of human lung cancer cell subline with different metastatic potential. Zhonghua Bing Li Xue Za Zhi 24: 136-138, 1995 (In Chinese).
22. Liu CR, Ma CS, Ning JY, You JF, Liao SL and Zheng J: Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl) 117: 213-218, 2004.
23. Xu HT, Wei Q, Liu Y, et al: Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Ann Surg Oncol 14: 3251-3259, 2007.
24. Cheung KK, Mok SC, Rezaie P and Chan WY: Dynamic expression of Dab2 in the mouse embryonic central nervous system. BMC Dev Biol 8: 76, 2008.
25. Martin JC, Herbert BS and Hocevar BA: Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br J Cancer 103: 1716-1723, 2010.
26. Bagadi SA, Prasad CP, Srivastava A, Prashad R, Gupta SD and Ralhan R: Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Res Treat 104: 277-286, 2007.
27. Xu HT, Yang LH, Li QC, Liu SL, Liu D, Xie XM and Wang EH: Disabled-2 and Axin are concurrently colocalized and underexpressed in lung cancers. Hum Pathol 42: 1491-1498, 2011.
28. Tong JH, Ng DC, Chau SL, et al: Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 10: 253, 2010.
29. Hannigan A, Smith P, Kalna G, et al: Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 120: 2842-2857, 2010.
30. Yang Y, Zhang Q, Xu F, Chang C and Li X: Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome. Eur J Haematol 89: 469-477, 2012.